Phase 1
N=32
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT05573230 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 — 332; 857 nanogram * hour per milliliter (ng*hr/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Midazolam (Drug); LY3502970 (Drug); Cyclosporine (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Eli Lilly and Company
- Primary completion
- Jan 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 |
332; 857 | — |
| PRIMARY PK: Maximum Observed Concentration (Cmax) of LY3502970 |
13.9; 18.4 | — |
Summary
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.
Eligibility Criteria
Inclusion Criteria
- Participants who are overtly healthy as determined by medical evaluation
- Participants with a body weight of 45 kilograms (kg) or more and body mass index (BMI) within the range of 18.5 to 35.0 kilograms per meter squared (kg/m²)
- Participants who have a hemoglobin level of at least 11.4 grams/deciliter (g/dL) for female participants and at least 12.5 g/dL for male participants
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
Exclusion Criteria
- Participants who have a significant history of or current cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
- Participants who regularly use known drugs of abuse
- Women who are lactating and who are of child-bearing potential
- Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
Data sourced from ClinicalTrials.gov (NCT05573230). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.